Jnana Therapeutics

Executive Summary

Jnana Therapeutics is a clinical-stage biotechnology company pioneering the discovery of small molecule drugs targeting solute carrier (SLC) transporters via its proprietary RAPID platform. Focused on immunology and metabolic diseases with high unmet need, the company aims to correct cellular dysfunction by modulating metabolite transport. Since its founding in 2017, Jnana has raised $107 million in private financing and advanced its lead program into Phase 1 clinical trials. The company's approach represents a novel modality in drug discovery, targeting a historically underexploited class of membrane proteins. With a robust platform and a pipeline addressing serious conditions such as autoimmune disorders and inborn errors of metabolism, Jnana is positioned to deliver transformative therapies. Key near-term milestones include initial Phase 1 data for its lead candidate and potential expansion into additional indications.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 safety and tolerability data readout for lead SLC program65% success
• Q1 2026Initiation of Phase 1/2 trial for second pipeline candidate70% success
• Q2 2026Potential partnership or licensing deal for RAPID platform50% success